Activation of Prostaglandin FP and EP2 Receptors Differently Modulates Myofibroblast Transition in a Model of Adult Primary Human Trabecular Meshwork Cells-Reference-Cited by-同舟云学术

Activation of Prostaglandin FP and EP2 Receptors Differently Modulates Myofibroblast Transition in a Model of Adult Primary Human Trabecular Meshwork Cells

Published:2016-04-15 Issue:4 Volume:57 Page:1816
ISSN:1552-5783
Container-title:Investigative Opthalmology & Visual Science
language:en
Short-container-title:Invest. Ophthalmol. Vis. Sci.

Author:

Kalouche Georges¹,Beguier Fanny²,Bakria Michael²,Melik-Parsadaniantz Stéphane²,Leriche Caroline³,Debeir Thomas³,Rostène William²,Baudouin Christophe⁴,Vigé Xavier⁵

Affiliation:

1. Sorbonne Universités Université Pierre et Marie Curie, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Institut de la Vision, Paris, France 2Sanofi Research & Development, Translational Sciences Uni

2. Sorbonne Universités Université Pierre et Marie Curie, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Institut de la Vision, Paris, France

3. Sanofi Research & Development, Ophthalmology, Paris, France

4. Sorbonne Universités Université Pierre et Marie Curie, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Institut de la Vision, Paris, France 4Quinze-Vingts National Ophthalmology Hospital, Paris, Fra

5. Sanofi Research & Development, Translational Sciences Unit, Chilly-Mazarin, France

Publisher

Association for Research in Vision and Ophthalmology (ARVO)

Subject

General Medicine

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Steroid-Induced Ocular Hypertension in Mice Is Differentially Reduced by Selective EP2, EP3, EP4, and IP Prostanoid Receptor Agonists;International Journal of Molecular Sciences;2024-03-15

2. Human experience and efficacy of omidenepag isopropyl (Eybelis®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug;Current Opinion in Pharmacology;2024-02

3. Recently Approved Drugs for Lowering and Controlling Intraocular Pressure to Reduce Vision Loss in Ocular Hypertensive and Glaucoma Patients;Pharmaceuticals;2023-05-26

4. FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma;Experimental Eye Research;2023-04

5. Intraocular nano-microscale drug delivery systems for glaucoma treatment: design strategies and recent progress;Journal of Nanobiotechnology;2023-03-10